Company / Current Liabilities
MoonLake Immunotherapeutics Current Liabilities History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$45.5M
FY2025
5-year range
$7.7M / $45.5M
FY2021-FY2025
Trend
+102.5%
vs FY2024
Sector context
#148 of 213
Health Care
What the data says
At $45M, MoonLake Immunotherapeutics's current liabilities ranks #66 of 213 in the Health Care sector. Current Liabilities has increased for 3 consecutive years, from $8M in FY2022 to $45M in FY2025.
Based on SEC 10-K filings.
$45M in FY2025 with a 5-year CAGR of +225.1%.
Increased from $10M to $45M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +81.0%
- 5-Year CAGR
- +225.1%
- 10-Year CAGR
- -
Sector benchmark
#66 of 213 in Health CareTop 31% of 213This company $45.5M Sector average $1.6B
▼
-97.1% below sector average
Key checks
Key Insights
- MoonLake Immunotherapeutics's current liabilities has grown for 3 consecutive years.
- 5-year CAGR of +225.1%, indicating consistent growth.
- In FY2025, current liabilities increased 102.5% year-over-year.
- Ranks #148 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.09 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $45.5M | +102.5% |
| FY2024 | $22.5M | +125.4% |
| FY2023 | $10.0M | +30.0% |
| FY2022 | $7.7M | -63.6% |
| FY2021 | $21.1M | +16745.4% |
| FY2020 | $125.2K | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026